Kidron Miriam 4

What Happened
Miriam Kidron, Chief Scientific Officer and Director of Oramed Pharmaceuticals (ORMP), received 19,000 shares of common stock on January 22, 2026 when performance stock units (PSUs) vested. The Form 4 records an exercise/conversion of a derivative (code M) for 19,000 shares at $0.00 — i.e., the shares were issued for no consideration upon vesting. This was an award/vesting event, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-22; reported on Form 4 filed 2026-01-29. (Filed 7 days after the transaction; later than the SEC’s typical 2-business-day Form 4 deadline.)
• Price: $0.00 per share (shares issued upon vesting, no cash paid).
• Shares involved: 19,000 shares converted/issued upon PSU vesting.
• Shares owned after transaction: not specified in this filing.
• Footnotes:
  • F1: The shares represent PSUs granted 12/31/2025 that vested on 1/22/2026 after the issuer’s stock reached a specified price; shares were received for no consideration.
  • F2: Each PSU entitled the holder to one share upon satisfaction of performance criteria.
• Transaction code: M (exercise or conversion of derivative security). The filing shows both an acquisition (conversion to common stock) and a corresponding derivative disposition entry reflecting that conversion.

Context
This was a routine compensation/award vesting (performance-based PSU payout), not a market buy or sale. Such vesting events reflect fulfillment of prior grant conditions and do not, by themselves, indicate an insider’s view on near-term stock direction. The reported filing date is later than the usual SEC Form 4 deadline, which investors may note for timeliness but does not change the nature of the award.